Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM). Dr Broyl highlights trials such as MUK Nine (NCT03188172)., and emphasizes the importance of reaching for measurable residual disease negativity in this group of patients. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
Treatment options for high-risk myeloma
